Entinostat

Entinostat

Names
Preferred IUPAC name (Pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
Other names SNDX-275; MS-275
Identifiers
CAS Number	209783-80-2  Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:132082  N
ChEMBL	ChEMBL27759  N
ChemSpider	4111  N
ECHA InfoCard	100.158.999
IUPHAR/BPS	7007
KEGG	D09338  Y
PubChem CID	4261
UNII	1ZNY4FKK9H  Y
CompTox Dashboard (EPA)	DTXSID0041068
InChI InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) N Key: INVTYAOGFAGBOE-UHFFFAOYSA-N N InChI=1/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) Key: INVTYAOGFAGBOE-UHFFFAOYAU
SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
Properties
Chemical formula	C21H20N4O3
Molar mass	376.4085 g/mol
Pharmacology
ATC code	L01XH05 ( WHO )
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N  verify  (what is  YN ?) Infobox references

Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. ^{[1] [2] [3] [4]}

Entinostat inhibits class I HDAC1 and HDAC3 with IC₅₀ of 0.51 μM and 1.7 μM, respectively. ^[5]

Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools. ^[6]

It has also been investigated as a potential male contraceptive drug. ^[7]

References

1. Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky SA, et al. (May 2008). "Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC)". Journal of Clinical Oncology. 26 (15_suppl): 19036-. doi:10.1200/jco.2008.26.15_suppl.19036.
2. Kiany S, Harrison D, Gordon N (2020). "The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma". Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. Vol. 1257. pp. 75–83. doi:10.1007/978-3-030-43032-0_7. ISBN   978-3-030-43031-3. PMID   32483732. S2CID   219169967.
3. Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. (November 2021). "Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies". Pharmacological Research. 173 105702. doi:10.1016/j.phrs.2021.105702. PMID   34102228. S2CID   235378858.
4. Lian B, Chen X, Shen K (2023). "Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer". Frontiers in Immunology. 14 1164514. doi: 10.3389/fimmu.2023.1164514 . PMC   10034161 . PMID   36969235.
5. US 2009/0263353,Maier T, Beckers T, Hummel RP, Feth M, Muller M, Bar T, Volz J,"Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles",issued 31 July 2012, assigned to 4SC AG 
6. "Company Prepares for Pivotal Phase 3 Study of Entinostat, Most Advanced HDAC Inhibitor in Development for ER+ Metastatic Breast Cancer" (PDF). Syndax Pharmaceuticals. 27 August 2013. Archived from the original (PDF) on 17 June 2016.
7. Hong SH, Castro G, Wang D, Nofsinger R, Kane M, Folias A, et al. (February 2024). "Targeting nuclear receptor corepressors for reversible male contraception". Proceedings of the National Academy of Sciences of the United States of America. 121 (9) e2320129121. Bibcode:2024PNAS..12120129H. doi: 10.1073/pnas.2320129121 . PMC   10907271 . PMID   38377195.